Acucela 4429-202 SEATTLE
Research Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration.
Sponsor: Acucela Inc
Principal Investigator: Mark J. Rivellese, M.D.
Description: The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compated to placebo in subjects with dry age-related macular degeneration.
Start Date: March 2013
Project Personnel: Leslie Marcus, CCRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084